Endeavor Clinical Trials (ECT), Midwest Clinical Research Center (MCRC), and St. Louis Clinical Trials (SLCT) were sites that participated in studies investigating a non-opioid postoperative pain medicine. The sponsor, Heron Therapeutics, has announced positive topline results from its completed Phase 3 studies of the investigational agent HTX-011 in subjects undergoing bunionectomy (Study 301/EPOCH1) and hernia repair (Study 302/EPOCH2). HTX-011 achieved all primary and key secondary endpoints in both Phase 3 trials, demonstrating statistically significant reductions in both pain intensity and the use of opioid rescue medications through 72 hours following surgery.

Click here to read about the positive topline results from the Phase 3 clinical trial.